First Tracks Biotherapeutics (TRAX) Stock Analysis & Winston Score
First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Weak (0/30)
- Growth: Data not available (0/20)
- Cash Flow: Data not available (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $36.52
Market Cap: $1.3B
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

